Ebola at 10,000, US Measles Nears PAHO Review, and $40-a-Year HIV PrEP Clears FDA

Today's roundup covers three evolving public-health crises — the Ebola outbreak's 10,000-case milestone, the approaching crossroads for US measles elimination status, and a dengue surge along Florida's Gulf Coast — alongside two landmark developments in treatment and drug access.

Wednesday, 4 November: Ebola Passes 10,000 Cases Across Four Countries

The 2026 Bundibugyo-strain Ebola outbreak has surpassed 10,000 documented infections across the Democratic Republic of the Congo, Uganda, and Kenya, according to Africa CDC data cited by Al Jazeera on 3 November. Total deaths stand at 5,376 — 5,372 of them in the DRC, two each in Kenya and Uganda. The DRC Ministry of Health, which tracks only laboratory-confirmed cases, places its own national figures at approximately 10,351 cases and more than 5,026 deaths as of 2 November, according to Latin Times.

Uganda's outbreak has been declared over after 20 cases and 2 deaths, but the virus remains active in the DRC, where 67 health zones across 8 provinces are affected. Isolated imported cases have been detected in Nigeria and France; neither country has reported sustained community transmission. The WHO classified this outbreak as a Public Health Emergency of International Concern in May 2026; it is now the second-largest Ebola outbreak on record after the 2013–2016 West Africa epidemic.

No licensed vaccine covers the Bundibugyo strain. A Phase 3 trial of an investigational candidate is underway, and the DRC has received 70,000 doses of Ervebo — approved for the Zaire strain but not Bundibugyo — for compassionate use. The CDC and ECDC continue to characterise the risk to travellers outside the affected region as low. For anyone transiting through the DRC, the US attestation rule that took effect 3 November requires a written declaration of non-presence in the country in the prior 21 days.

Wednesday, 4 November: US Measles at 4,852 Cases; PAHO Reviews Elimination Status Next Week

The United States measles outbreak has reached 4,852 confirmed cases, the CDC reported as of 29 October, with some independent trackers placing the figure above 5,000. The outbreak has spread to at least 45 states, produced at least three CDC-confirmed deaths (Pennsylvania authorities report five), and resulted in 511 hospitalisations — an 11% hospitalisation rate among confirmed cases. Ninety-six per cent of infections occurred in unvaccinated individuals or people of unknown vaccination status.

The Pan American Health Organization (PAHO) Regional Verification Commission is scheduled to meet 10–13 November to assess whether the United States can retain the measles elimination status it has held since 2000. Canada lost that status in November 2025 after endemic transmission was established there, and the Americas region as a whole simultaneously lost its designation as measles-free. For the US, the review will determine whether the Texas outbreak that began on 20 January 2025, and its extensions into more than 40 other states, constitute re-established endemic circulation — a determination requiring full genome sequencing and epidemiological chain analysis. While the outcome is not predetermined, the scale of the 2026 surge — far exceeding any year since elimination — is considered strong evidence of interrupted elimination.

The two-dose measles-mumps-rubella (MMR) vaccine is 97% effective against measles. EU and Cyprus health authorities continue to recommend catch-up vaccination for anyone born after 1970 who cannot document two doses, and for unvaccinated children from infancy onward.

Wednesday, 4 November: FDA Grants Tentative Approval for $40-a-Year Generic Lenacapavir

The US Food and Drug Administration has granted Dr. Reddy's Laboratories a tentative approval for a generic version of lenacapavir, the twice-yearly injectable HIV pre-exposure prophylaxis (PrEP), specifically for use in 120 low- and middle-income countries. The generic is priced at approximately $40 per person per year. Gilead's branded Yeztugo carries a US list price of about $28,218 a year — a 700-fold difference.

Lenacapavir is a capsid inhibitor that suppresses HIV replication for up to six months per dose, requiring only two injections annually. Its landmark PURPOSE 1 trial — enrolling women across sub-Saharan Africa — and PURPOSE 2 trial — a global cohort including cisgender men, transgender women, and gender-non-binary participants — both demonstrated near-complete protection against HIV acquisition. The infrequent dosing schedule is a substantial advantage over daily oral PrEP in settings where maintaining daily adherence is difficult.

Tentative approval is the FDA's standard designation when a generic meets safety and efficacy standards but cannot be sold in the US domestic market because the originator product remains under patent. Dr. Reddy's application was supported by Unitaid and CHAI. Gilead granted voluntary licences to six manufacturers, including Dr. Reddy's, in late 2024. The tentative approval accelerates regulatory review in recipient countries but does not substitute for national approvals. For countries in the eastern Mediterranean and North Africa — where HIV incidence is rising and oral PrEP uptake remains low — the availability of affordable injectable PrEP at scale carries significant public-health implications.

Wednesday, 4 November: PROGRESS Trial — Early TAVR Cuts Heart-Failure Risk in Moderate Aortic Stenosis

A major randomised trial published in the New England Journal of Medicine on 2 November and presented at TCT 2026 in Washington found that early transcatheter aortic valve replacement (TAVR) significantly reduced the composite of death or heart-failure events compared with clinical surveillance in patients with moderate aortic stenosis and at least one high-risk feature.

The PROGRESS trial enrolled 744 patients aged 65 and older at 74 centres across six countries. All had moderate — not yet severe — aortic stenosis, plus at least one risk marker such as reduced ejection fraction, elevated BNP, or severe diastolic dysfunction. Patients were randomised to early TAVR with the Edwards SAPIEN 3 valve or to routine clinical observation. The primary composite endpoint of death or heart-failure hospitalisation at two years occurred in 16.7% of TAVR patients versus 23.9% of surveillance patients — a 33% relative risk reduction. The difference was driven primarily by heart-failure hospitalisations; overall mortality did not differ significantly between arms. No deaths or disabling strokes were attributed to the procedure at 30 days.

Fifty-seven per cent of surveillance-arm patients crossed over to aortic valve replacement during the two years, reflecting the natural progression of moderate stenosis and potentially attenuating the mortality signal. As Healio notes, the trial was sponsored by Edwards Lifesciences. Experts caution that the findings do not imply universal early intervention: the enrolled population was selected for specific at-risk features, and guideline bodies have not yet updated their recommendations in response to the data.

Wednesday, 4 November: Florida Dengue — Largest Outbreak in Continental US Since the 1930s

Florida's 2026 dengue season has become the largest locally acquired dengue outbreak in the continental United States in nearly a century. The Florida Department of Health and CDC data report more than 485 confirmed locally acquired cases among residents this year, with Hillsborough County (Tampa) and Miami-Dade County accounting for the highest burdens. One death has been reported. PBS NewsHour reported the outbreak as the largest in the continental United States since the 1930s.

Dengue is transmitted by Aedes aegypti and Aedes albopictus mosquitoes; it does not spread directly between people. Florida's warm, humid climate and urban density of Aedes aegypti make sustained local transmission possible in a way that is rare elsewhere on the North American mainland. The responsible serotype is DENV-2, which immunologists consider one of the more clinically severe strains. Dengue infections can range from asymptomatic or flu-like illness to severe dengue haemorrhagic fever in a minority of cases; a prior infection with a different serotype is a key risk factor for severe disease.

The one FDA-approved dengue vaccine in the United States — Dengvaxia by Sanofi — is licensed only for people aged 9–45 with laboratory-confirmed prior dengue infection; it is not a tool for primary prevention in travellers. For visitors from Cyprus, Greece, or other Mediterranean countries travelling to affected parts of Florida, standard mosquito-prevention measures — DEET- or picaridin-based repellent, long sleeves during peak biting hours (early morning and late afternoon), and accommodations with effective screens or air conditioning — remain the primary protective tools.

---

This roundup is journalistic reporting and does not constitute medical advice. Readers should consult a qualified clinician before making any change to a treatment, vaccination, or medication plan.